Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1980 2
1982 2
1983 1
1984 1
1985 2
1988 2
1996 1
1997 1
1998 1
1999 1
2001 2
2004 1
2009 1
2010 1
2012 2
2013 1
2014 1
2015 4
2016 1
2018 1
2020 1
2021 4
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

34 results
Results by year
Filters applied: . Clear all
Page 1
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device.
Olgasi C, Borsotti C, Merlin S, Bergmann T, Bittorf P, Adewoye AB, Wragg N, Patterson K, Calabria A, Benedicenti F, Cucci A, Borchiellini A, Pollio B, Montini E, Mazzuca DM, Zierau M, Stolzing A, Toleikis PM, Braspenning J, Follenzi A. Olgasi C, et al. Among authors: cucci a. Mol Ther Methods Clin Dev. 2021 Nov 3;23:551-566. doi: 10.1016/j.omtm.2021.10.015. eCollection 2021 Dec 10. Mol Ther Methods Clin Dev. 2021. PMID: 34853801 Free PMC article.
Deciphering the Ets-1/2-mediated transcriptional regulation of F8 gene identifies a minimal F8 promoter for hemophilia A gene therapy.
Famà R, Borroni E, Merlin S, Airoldi C, Pignani S, Cucci A, Corà D, Bruscaggin V, Scardellato S, Faletti S, Pelicci G, Pinotti M, Walker GE, Follenzi A. Famà R, et al. Among authors: cucci a. Haematologica. 2021 Jun 1;106(6):1624-1635. doi: 10.3324/haematol.2019.239202. Haematologica. 2021. PMID: 32467137 Free PMC article.
Patient-Specific iPSC-Derived Endothelial Cells Provide Long-Term Phenotypic Correction of Hemophilia A.
Olgasi C, Talmon M, Merlin S, Cucci A, Richaud-Patin Y, Ranaldo G, Colangelo D, Di Scipio F, Berta GN, Borsotti C, Valeri F, Faraldi F, Prat M, Messina M, Schinco P, Lombardo A, Raya A, Follenzi A. Olgasi C, et al. Among authors: cucci a. Stem Cell Reports. 2018 Dec 11;11(6):1391-1406. doi: 10.1016/j.stemcr.2018.10.012. Epub 2018 Nov 8. Stem Cell Reports. 2018. PMID: 30416049 Free PMC article.
Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1b.
Durelli L, Barbero P, Cucci A, Ferrero B, Ricci A, Contessa G, De Mercanti S, Ripellino P, Lapuma D, Viglietta E, Bergui M, Versino E, Clerico M; OPTIMS Trial NAb Sub-Study Group. Durelli L, et al. Among authors: cucci a. Expert Opin Biol Ther. 2009 Apr;9(4):387-97. doi: 10.1517/14712590902762781. Expert Opin Biol Ther. 2009. PMID: 19278300 Clinical Trial.
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.
De Mercanti S, Rolla S, Cucci A, Bardina V, Cocco E, Vladic A, Soldo-Butkovic S, Habek M, Adamec I, Horakova D, Annovazzi P, Novelli F, Durelli L, Clerico M. De Mercanti S, et al. Among authors: cucci a. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 21;3(1):e194. doi: 10.1212/NXI.0000000000000194. eCollection 2016 Feb. Neurol Neuroimmunol Neuroinflamm. 2016. PMID: 26819963 Free PMC article.
34 results